Tìm theo
Aldesleukin
Các tên gọi khác (4 ) :
  • IL-2
  • Interleukin-2 precursor
  • T-cell growth factor
  • TCGF
Thuốc điều trị ung thư
Thuốc Gốc
Biotech
CAS: 85898-30-2
ATC: L03AC01
ĐG : Bayer Healthcare , http://www.bayerhealthcare.com
CTHH: C690H1115N177O202S6
PTK: 15314.8000
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C690H1115N177O202S6
Phân tử khối
15314.8000
Độ kỵ nước
-0.192
Điểm đẳng điện tích
7.31
Dược Lực Học : Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.
Cơ Chế Tác Dụng : Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.
Dược Động Học :

▧ Volume of Distribution :
0.18 l/kg
▧ Route of Elimination :
The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.
▧ Half Life :
13 min-85 min
Chỉ Định : For treatment of adults with metastatic renal cell carcinoma.
Tương Tác Thuốc :
  • Clobetasol propionate Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
  • Clocortolone Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
  • Clozapine Avoid combination due to enhanced adverse effects of clozapine, especially the risk of agranulocytosis.
  • Corticotropin Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
  • Duloxetine Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Chiron Corp
    Sản phẩm biệt dược : Proleukin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00041
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0078-0495-61
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/M11144
PharmGKB
http://www.pharmgkb.org/drug/PA448081
Wikipedia
http://en.wikipedia.org/wiki/Aldesleukin
RxList
http://www.rxlist.com/cgi/generic2/aldesleukin.htm
Drugs.com
http://www.drugs.com/cdi/aldesleukin.html
... loading
... loading